Pharmafile Logo

The science is shifting in oncology: Are you ready to evolve with it?

August 19, 2025 | Inizio, oncology 

- PMLiVE

Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke.

This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic breast cancer introduced a ground-breaking endpoint – patients progression-free at four years – challenging long-held assumptions.

Key themes included the rise of CAR-T therapies in solid tumors, the dominance of ADCs, and the expanding role of biomarkers in driving precision medicine. Emerging tools like AI-powered biomarker detection and ctDNA for real-time monitoring are reshaping how sequencing, resistance, and adaptive treatments are approached.

Beyond the science, ASCO® 2025 underscored a new strategic imperative: it’s no longer enough to track progress – we must rethink how we plan, communicate, and act on these advances.

Read Patty’s full article here. Watch Inizio’s webinar recap Beyond the booth: Big ideas, smart spaces & strategic insights from ASCO® 2025 on demand for the full breakdown.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Preparing for ASH 2025: Pharma’s role in hematology innovation

As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

AI without limits: A smarter, integrated approach to Medical Affairs

At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...

What to expect from Obesity Week 2025: Key trends shaping the future of obesity care

Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.

AI with intent: How Inizio is redefining pharma through precision and partnership

At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...

Leading the future of Intelligent Commercializationâ„¢: Where proprietary data, tech, and AI meet expert insight

Inizio is leading the way in Intelligent Commercializationâ„¢ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.

Delivering purposeful solutions at Obesity Week 2025

We’re attending Obesity Week 2025, the world’s leading event dedicated to obesity research and care, to showcase how our integrated expertise is advancing progress in obesity and cardiometabolic health.

Inizio strengthens executive team with new leadership appointments

Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercializationâ„¢...

Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards

Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across...

Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care

Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.

Inizio appoints Ryan Quigley as CEO

Inizio have appointed Ryan Quigley as Chief Executive Officer, effective 9 September 2025. Paul Taaffe will remain closely involved with the company as an Advisor and board member going forward. ...